Najat Khan

Rene Haas, CEO of Arm Holdings, discusses the pivotal role of energy-efficient processors in AI infrastructure investments. Rachel Metz shares insights on the collaborations among tech giants like SoftBank and OpenAI, emphasizing the transformative potential of government support in AI. Najat Khan explains how AI is revolutionizing drug discovery, speeding up the path to clinical trials. Ben Harburg analyzes the implications of new investment strategies in China, while Rich Greenfield evaluates Netflix's growth amidst intense streaming competition.

Najat Khan, CEO and President of Recursion Pharmaceuticals and former Johnson & Johnson R&D leader, explains how AI must prove itself by delivering real medicines. She discusses where AI is already adding value across biology, chemistry and clinical work. Topics include agentic AI for lab workflows, out-of-domain prediction, virtual cells and precompetitive consortia to build stronger shared data foundations.

Najat Khan, Chief R&D Officer and Chief Commercial Officer at Recursion Pharmaceuticals, dives into the revolutionary impact of AI on drug discovery. She shares insights on how tech-driven biotech firms are transforming the pharmaceutical landscape. The discussion highlights the vital role of AI in clinical development and data integration for better patient outcomes. Exploring challenges and innovations, Najat emphasizes the need for a skilled workforce that bridges science and technology, paving the way for future biotech advancements.